RE: Pipeline Update24 Aug 2019 11:34
Thankyou for posting amones and I agree with your sentiment Saigon! It appears this Secondary listing is overhanging the market and may continue to do so for some time yet, which is disappointing, but outside Chi-Med's control of course.
I still believe the Company is significantly undervalued compared to its peers who are at similar stages in their development - I refer to Exelixis, Beigene, Galapagos and Bluebird in particular when doing a comparison. Each
has differing financials and depth of pipeline but some valuations are very different to Chi-Med. The Secondary listing, postponed HK listing and U.S. China trade wars could all be having an impact.
I remain very bullish on the Company and it continues to be my largest strategic long term investment.